361 related articles for article (PubMed ID: 20824831)
21. [Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
Decalf V; Sabbah L; Lafont A; Danchin N; Durand E
Arch Mal Coeur Vaiss; 2007 Dec; 100(12):1006-12. PubMed ID: 18223514
[TBL] [Abstract][Full Text] [Related]
22. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era.
Fanning JP; Nyong J; Scott IA; Aroney CN; Walters DL
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004815. PubMed ID: 27226069
[TBL] [Abstract][Full Text] [Related]
23. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
26. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
28. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
[TBL] [Abstract][Full Text] [Related]
29. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
30. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
31. Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.
Ali-Hasan-Al-Saegh S; Mirhosseini SJ; Shahidzadeh A; Rahimizadeh E; Sarrafan-Chaharsoughi Z; Ghodratipour Z; Lotfaliani M; Rezaeisadrabadi M; Dehghan HR; Bireta C; Weymann A; Sabashnikov A; Popov AF
Kardiol Pol; 2016; 74(2):104-18. PubMed ID: 26202532
[TBL] [Abstract][Full Text] [Related]
32. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
35. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
37. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Ciccone A; Abraha I; Santilli I
Cochrane Database Syst Rev; 2006 Oct; (4):CD005208. PubMed ID: 17054247
[TBL] [Abstract][Full Text] [Related]
38. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
39. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
Hillegass WB; Newman AR; Raco DL
Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
Navarese EP; Schulze V; Andreotti F; Kowalewski M; Kołodziejczak M; Kandzari DE; Rassaf T; Gorny B; Brockmeyer M; Meyer C; Berti S; Kubica J; Kelm M; Valgimigli M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):201-213. PubMed ID: 25616926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
